Latest News
TomCo Energy Shares Fell 3% on Second Loan Repayment Extension
Key points: The TomCo Energy shares fell 3% as it extended its loan repayment date. The lender is having trouble securing new funding for its TSHII
Ceres Power To Produce Hydrogen With Shell – Does This Close The Energy Circle?
Key points: Ceres Power has signed a deal with Shell to produce green hydrogen This is the other side of the fuel cell business, hydrogen production not consumption If i
Rainbow Rare Earths – Have They Cracked An Entirely Different Rare Earth Source?
Key points: Rainbow has revealed their planned rare earth extraction technology It looks like it will work technically, there's a good chance it will economically The bi
The Amigo Loans Share Price Surged 28% as It Rebrands to RewardRate
Key points: The Amigo Loans share price spiked 28% higher on the latest update. The lender revealed that it would resume lending as RewardRate.
Agile Therapeutics (AGRX) Stock Price Surged 38.3% Despite No News
Key points: Agile Therapeutics (AGRX) stock price surged 38.3% despite no news. The company benefitted from the Supreme Court’s decision in Roe v.
The Evofem Biosciences (EVFM) Stock Price Soared 69.2%. Here’s Why.
Key points: Evofem Biosciences (EVFM) stock price soared by 69.2% today. Investors are betting that it will benefit from the Supreme Court decision
Petro Matad (MATD) Shares Plunged 10% on FY21 Results. What’s Next?
Key points: The Petro Matad share price plunged 10.5% on its full-year results. MATD shares fell despite the oil firm’s positive annual results for
Binance US to Offer Zero-Fee Bitcoin (BTC) trading
Key points: Binance.US to offer zero-fee bitcoin (BTC) trading Coinbase Stock Dipped On This News Price War to Continue in “Crypto Winter” key point
Ipsens’ Epizyme Bid Gives A $1 CRV Option For 10 cents – Should We Buy In?
Key points: Ipsen has bid for Epizyme at $1.45 per share cash There's also a potential $1 contingent value right That $1 is currently valued at 10 cents
ImmuPharma (IMM) Shares Fell 12% Despite an FDA Update. Is It a Buy?
Key points: ImmuPharma shares plunged 12% despite a positive FDA update. The company is waiting for the FDDA to approve its subsequent trial.
Nifty Fifty Up 1% – Is The INDY ETF The Way To Trade This?
Key points: The INDY ETF gives exposure to the Indian markets The Nifty Fifty is the 50 major large caps there Indian markets are volatile, making trading possibly intere
Symphony Environmental’s (SYM) Share Price Surged 6.4%. Here’s Why.
Key points: The Symphony Enrvionemnetal share price surged 6.4% today. The company just won a legal battle in Peru with significant results.
Is 4D Pharma Now A Dead Parrot, Not Just Pining For The Fjords?
Key points: 4D Pharma shares were suspended on Friday at lunchtime Then after close came the news that the company was in administration The question now is, well, is the
G7 Russian Gold Ban – How Will This Affect Polymetal?
Key points: The G7 has announced a ban on new sales of Russian gold We might think this will have a significant effect upon Polymetal But Russian gold is already not good
ToughBuilt (TBLT) Stock Rallied 130% on a $6M Capital Raise. Is It a Buy?
Key points: ToughBuilt (TBLT) stock price soared 130% after raising $6 million. Investors cheered the capital raise despite diluting current shareh
The Zendesk (ZEN) Stock Price Rallied 30% After a $10.2Bn Takeover
Key points: The Zendesk (ZEN) stock price rallied 30% after a $10.2bn takeover. Unfortunately, the firm had turned down a $17 billion offer in Febr
Sundial Growers (SNDL) Stock Has Risen 25.9% in a Week. What’s Next?
Key points: Sundial Growers (SNDL) shares have risen 25.9% in a week. In addition, the stock appears to have recently bottomed.
National Grid (NG) Shares Have Fallen 18% Since May. Can It Recover?
Key points: National Grid (NG) shares have fallen 18% since May on the windfall tax. Investors are worried that the tax will be extended to electri
MGC Pharmaceuticals (MXC) Share Price Rallied 7.8% Today. Here’s Why.
Key points: MGC Pharmaceuticals (MXC) share price rallied 7.8% on the latest update. The pharma company will start clinical trials of its COVID-19
Quotient Drops 30% On Stock Offering – What Comes Next?
Key points: Quotient stock jumped 95% at one point earlier this week The result of a revenue beat and sales forecasts Quotient is now issuing new stock dragging the price